|
1
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of
tumours of haematopoietic and lymphoid tissues. 2. 4th. IARC;
2008
|
|
2
|
Nucifora G, Laricchia-Robbio L and Senyuk
V: EVI1 and hematopoietic disorders: History and perspectives.
Gene. 368:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin CC, Cortes J, Barkoh B, Hayes K,
Kantarjian H and Jones D: t(3;21)(q26;q22) in myeloid leukemia: An
aggressive syndrome of blast transformation associated with
hydroxyurea or antimetabolite therapy. Cancer. 106:1730–1738. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maki K, Yamagata T and Mitani K: Role of
the RUNX1-EVI1 fusion gene in leukemogenesis. Cancer Sci.
99:1878–1883. 2008.PubMed/NCBI
|
|
5
|
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C,
Lu G and Lin P: Myelodysplastic syndrome/acute myeloid leukemia
with t(3;21)(q26.2;q22) is commonly a therapy-related disease
associated with poor outcome. Am J Clin Pathol. 138:146–152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glass C, Wilson M, Gonzalez R, Zhang Y and
Perkins AS: The role of EVI1 in myeloid malignancies. Blood Cell
Mol Dis. 53:67–76. 2014. View Article : Google Scholar
|
|
7
|
Hinai AA and Valk PJ: Review: Aberrant
EVI1 expression in acute myeloid leukaemia. Br J Haematol.
172:870–888. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morishita K, Parker DS, Mucenski ML,
Jenkins NA, Copeland NG and Ihle JN: Retroviral activation of a
novel gene encoding a zinc finger protein in IL-3-dependent myeloid
leukemia cell lines. Cell. 54:831–840. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gröschel S, Sanders MA, Hoogenboezem R, De
Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M,
Avellino R, van Lom K, et al: A single oncogenic enhancer
rearrangement causes concomitant EVI1 and GATA2 deregulation in
leukemia. Cell. 157:369–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamazaki H, Suzuki M, Otsuki A, Shimizu R,
Bresnick EH, Engel JD and Yamamoto M: A remote GATA2 hematopoietic
enhancer drives leukemogenesis in inv(3)(q21;q26) by activating
EVI1 expression. Cancer Cell. 25:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitani K, Ogawa S, Tanaka T, Miyoshi H,
Kurokawa M, Mano H, Yazaki Y, Ohki M and Hirai H: Generation of the
AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic
crisis in chronic myelocytic leukemia. EMBO J. 13:504–510.
1994.PubMed/NCBI
|
|
12
|
Nucifora G, Begy CR, Kobayashi H, Roulston
D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN and Rowley
JD: Consistent intergenic splicing and production of multiple
transcripts between AML1 at 21q22 and unrelated genes at 3q26 in
(3;21)(q26;q22) translocations. Proc Natl Acad Sci USA. 91:pp.
4004–4008. 1994; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motomura S, Fujisawa S, Tsunooka S,
Fujimaki K, Harano H, Mohri H, Okubo T, Fujita H, Maruta A and
Kodama F: Translocation (3;21)(q26;q22) in de novo acute
myelogenous leukemia. Leukemia. 11:172–173. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park TS, Choi JR, Yoon SH, Song J, Kim J,
Kim SJ, Kwon O and Min YH: Acute promyelocytic leukemia relapsing
as secondary acute myelogenous leukemia with translocation
t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript. Cancer
Genet Cytogenet. 187:61–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang JJ, Cho SY, Suh JT, Lee HJ, Lee WI,
Yoon HJ, Baek SK and Park TS: Detection of RUNX1-MECOM fusion gene
and t(3;21) in a very elderly patient having acute myeloid leukemia
with myelodysplasia-related changes. Ann Lab Med. 32:362–365. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Forghieri F, Bigliardi S, Morselli M,
Potenza L, Fantuzzi V, Faglioni L, Nasillo V, Messerotti A, Paolini
A and Luppi M: An unusual case of splenomegaly and increased
lactate dehydrogenase heralding acute myeloid leukemia with
eosinophilia and RUNX1-MECOM fusion transcripts. Leuk Res Rep.
3:83–85. 2014.PubMed/NCBI
|
|
17
|
Nogami A, Oshikawa G, Okada K, Fukutake S,
Umezawa Y, Nagao T, Kurosu T and Miura O: FLT3-ITD confers
resistance to the PI3K/Akt pathway inhibitors by protecting the
mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid
leukemia. Oncotarget. 6:9189–9205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997.PubMed/NCBI
|
|
19
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Malcovati L, Porta MG, Pascutto C,
Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L,
Maffioli M, Bernasconi P, et al: Prognostic factors and life
expectancy in myelodysplastic syndromes classified according to WHO
criteria: A basis for clinical decision making. J Clin Oncol.
23:7594–7603. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitelman F, Johansson B and Mertens FE:
Mitelman Database of Chromosome Aberrations and Gene Fusions in
Cancer. http://cgap
ncinihgov/Chromosomes/MitelmanFebruary 16–2016
|
|
22
|
Ichikawa A, Arakawa F, Kiyasu J, Sato K,
Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y,
et al: Methotrexate/iatrogenic lymphoproliferative disorders in
rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality
are important predictors of disease progression and regression. Eur
J Haematol. 91:20–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pointud P, Prudat M and Peron JM: Acute
leukemia after low dose methotrexate therapy in a patient with
rheumatoid arthritis. J Rheumatol. 20:1215–1216. 1993.PubMed/NCBI
|
|
24
|
Kerr L Dubin, Troy K and Isola L: Temporal
association between the use of methotrexate and development of
leukemia in 2 patients with rheumatoid arthritis. J Rheumatol.
22:2356–2358. 1995.PubMed/NCBI
|
|
25
|
Rosenthal NS and Farhi DC: Myelodysplastic
syndromes and acute myeloid leukemia in connective tissue disease
after single-agent chemotherapy. Am J Clin Pathol. 106:676–679.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kolte B, Baer AN, Sait SN, O'Loughlin KL,
Stewart CC, Barcos M, Wetzler M and Baer MR: Acute myeloid leukemia
in the setting of low dose weekly methotrexate therapy for
rheumatoid arthritis. Leuk Lymphoma. 42:371–378. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi BR, Ahn MJ, Lee WS, Kim TH, Bae SC
and Jun JB: Acute erythroleukemia in a rheumatoid arthritis patient
during low-dose methotrexate therapy. Rheumatol Int. 25:311–313.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al-Anazi KA, Eltayeb KI, Bakr M and
Al-Mohareb FI: Methotrexate-induced acute leukemia: Report of three
cases and review of the literature. Clin Med Case Rep. 2:43–49.
2009.PubMed/NCBI
|
|
29
|
Sakai T, Tamura S, Miyoshi T, Nesumi N,
Nagai K and Oshima K: Development of myeloid sarcoma after
long-term methotrexate use for rheumatoid arthritis. Int J Hematol.
99:493–498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson LA, Pfeiffer RM, Landgren O,
Gadalla S, Berndt SI and Engels EA: Risks of myeloid malignancies
in patients with autoimmune conditions. Br J Cancer. 100:822–828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokita K, Maki K and Mitani K: RUNX1/EVI1,
which blocks myeloid differentiation, inhibits CCAAT-enhancer
binding protein alpha function. Cancer Sci. 98:1752–1757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maicas M, Vázquez I, Vicente C,
García-Sánchez MA, Marcotegui N, Urquiza L, Calasanz MJ and Odero
MD: Functional characterization of the promoter region of the human
EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly
regulate its transcription. Oncogene. 32:2069–2078. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Helbling D, Mueller BU, Timchenko NA,
Hagemeijer A, Jotterand M, Meyer-Monard S, Lister A, Rowley JD,
Huegli B, Fey MF and Pabst T: The leukemic fusion gene
AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by
activation of Calreticulin. Proc Natl Acad Sci USA. 101:pp.
13312–13317. 2004; View Article : Google Scholar : PubMed/NCBI
|
